Compared to the pace of innovation in electronic consumer products, the pace of innovation for medical devices is lagging behind. It is the overarching objective of Moore4Medical to accelerate innovation in electronic medical devices. Moore4Medical emerging medical applications that offer significant new opportunities for the ECS industry including: active implantable devices (bioelectronic medicines), organ-on-chip, drug adherence monitoring, smart ultrasound, radiation free interventions and continuous monitoring. The new technologies will help fighting the increasing cost of healthcare by: reducing the need for hospitalization, helping the development of personalized therapies, and realizing intelligent point-of-care diagnostic tools. Moore4Medical will bring together 68 specialists from 12 countries who will develop open technology platforms for these emerging fields to help them bridge “the Valley of Death” in shorter time and at lower cost. Open technology platforms used by multiple users for multiple applications with the prospect of medium to high volume markets are an attractive proposition for the European ECS industry. The combination of typical MedTech applications with an ECS style platform approach will enhance the competitiveness for the emerging medical domains addressed in Moore4Medical. With value and IP moving from the technology level towards applications and solutions, defragmentation and open technology platforms will be key in acquiring and maintaining a premier position for Europe in the forefront of affordable healthcare

The burden of cardiovascular disease (CVD) on society is huge with >85 million people affected in Europe. The overall prevalence continues to grow due to unhealthy lifestyles and population aging. Heart failure (HF) is the final common pathway of all CVD and has a 5 year mortality rate of 20-50% despite significant advances in therapy. iCARE4CVD aims to address this burden by contributing to three essential steps to improve the current care pathways, covering all stages from early risk to established HF: 1) early diagnosis to identify patients at risk of CVD and divide them into clinically meaningful subgroups; 2) risk stratification for these subgroups to define the urgency for intervention; and 3) prediction of treatment response for each subgroup. This will be achieved by the following steps: clinical partners will provide a large set of cohorts including >1,000,000 patients with a wide range of biomarkers (e.g. digital, blood, imaging). Anonymous access to data will be enabled by using a blockchain-supported federated database. Artificial intelligence-based modeling also considering patient relevant factors will assess changes in risk and stratify patients according to their individual responses to therapy. Results will then be prospectively validated in new and ongoing large cohorts and a pilot trial to test the prediction of treatment response by using multiple biomarkers going beyond current risk prediction (such as SCORE) towards individualized therapy. Results will be used to provide novel decision tools for each step targeting newly identified subgroups and as a blueprint for innovative future trials to individualise prevention and therapy. Patient involvement is key in every part of iCARE4CVD (e.g. patient advisory board, country-specific Patient Panels) to build a motivational framework for self-care by patients. The project brings together an EU-wide consortium with the needed resources and expertise from the public and private side to bring iCARE4CVD to success.

There is increasing focus on the well being of mothers and babies, both before and after delivery and early detection of pathologies to prevent mother and perinatal morbidity and mortality. The overall well being of mothers also has longer term impact: women who remain healthy during pregnancy and after birth are more likely to stay healthy later in life and have better birth outcomes, also influencing the infancy, childhood and adulthood of their children. NewLife project will develop new remote non-invasive monitoring solutions for ensuring the health of mothers and babies before and after birth. The target is to develop emerging non-invasive methods for gathering vital data and analysing it with advanced AI/ML methods, to be able to secure life in its most vulnerable phase. For clinical acceptance, the developed solutions need to be well integrated to the clinical workflows, with proper data integration, security, safety, and medical qualification. The technologies and solutions developed are demonstrated in five use cases for both hospitals and personalized monitoring in home environments: 1) Pregnancy & parent companion, 2) Smart garment for monitoring of pregnancies & complications, 3) Fetal monitoring patch for high-risk pregnancies, 4) Newborn monitoring with smart clothes, and 5) Newborn monitoring -well being in bed. With the developed solutions, NewLife project will contribute to the disruption of the health care models: by focusing on preventive actions rather than treating diseases, and moving healthcare from hospitals to home.

The strong drive for more complex systems and more advanced packaging, including optics and photonics, creates a chance to retain the manufacturing and packaging value chain to Europe - or even start to bring it back. APPLAUSE supports this by building on the European expertise in advanced packaging and assembly to develop new tools, methods and processes for high volume mass manufacturing of electrical and optical components. The technologies will be piloted in 5 industrial Use Cases, related to 1. Substantially smaller 3D integrated ambient light sensor for mobile and wearable applications (AMS) 2. High performance, low cost, uncooled thermal IR sensor for automotive and surveillance applications (IDEAS) 3. High speed Datacom transceivers with reduced manufacturing costs (DustPhotonics) 4. Flexible cardiac monitoring patch and miniaturized cardiac implants with advanced monitoring capabilities (GE Healthcare and Cardiaccs). The APPLAUSE consortium is built of a number of leading experts from European electronics packaging companies representing different value chain levels related to advanced packaging and smart system integration. The parties have complementary expertise in conception, design, packaging, testing and manufacturing of electronic components, as well as a wide range of expertise from several different end use areas. The unique European ecosystem established within the consortium represents the competitive, leading edge of the technologies available.

CardioSignal is a suite of breakthrough smartphone apps to detect heart conditions and save lives. It will be the first technology to identify atrial fibrillation (AFib), heart failure (HF) and coronary artery disease (CAD) - all without extra hardware. Using CardioSignal, people at risk of serious cardiac conditions and their doctors can monitor their heart function quickly and at low cost. The app measures chest vibrations and analyses data in the cloud. Patients with abnormalities are directed to immediate medical attention. It outperforms Apple Watch, which cannot accurately detect AFib and is incapable of detecting CAD & HF. Context: 49 million Europeans suffer from cardiovascular conditions annually, resulting in heart attacks and stroke. Early detection and follow-up could save millions of lives. Solution: CardioSignal apps use a smartphone's gyroscope and accelerometer to measure heart activity across six parameters. Users place the smartphone on their chest for 60 seconds. The cloud-based platform analyses data and returns a diagnosis. Business Model: (1) HF & CAD: B2B sales to private healthcare companies, big pharma, diagnostics firms. Pharma companies Roche and Novartis are ready to conduct trials, leading to major contracts. (2) AFib: B2B2C sales. Market Opportunity: 300M potential users in EU, 1B globally. €4.2B TAM in target countries. Company: Precordior Oy, a medtech spin-off from University of Turku, Finland. Team of 13 highly experienced cardiologists, technologists and sales experts. €3M in funding secured, ready to grow. Progress: V1 app for AFib detection complete, clinically proven. 19 patents secured. EU Seal of Excellence. Project: Develop new apps for HF and CAD. Obtain regulatory approval. Launch across EU; US and China to follow. Impact by 2025: 1.27M at-risk patients and doctors using app daily in EU, USA and China. €85M revenue, €38M EBITDA, 250 FTE.